Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 21;23(19):3496-3504.
doi: 10.3748/wjg.v23.i19.3496.

Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma

Ting Wang  1 , Mei Liu  1 , Su-Jun Zheng  1 , Dan-Dan Bian  1 , Jin-Yan Zhang  1 , Jia Yao  1 , Qing-Fen Zheng  1 , A-Meng Shi  1 , Wen-Han Li  1 , Lu Li  1 , Yu Chen  1 , Jin-Hai Wang  1 , Zhong-Ping Duan  1 , Lei Dong  1
Affiliations

Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma

Ting Wang et al. World J Gastroenterol. .

Abstract

Aim: To determine the prevalence and diagnostic value of autoantibodies in α-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC).

Methods: Fifty-six serum samples from AFP-negative HCC cases, 86 from AFP-positive HCC cases, 168 from chronic liver disease cases, and 59 from normal human controls were included in this study. Autoantibodies to nucleophosmin (NPM)1, 14-3-3zeta and mouse double minute 2 homolog (MDM2) proteins in AFP-negative HCC serum were evaluated by enzyme-linked immunosorbent assay. Partially positive sera were further evaluated by western blotting. Immunohistochemistry was used to detect the expression of three tumor-associated antigens (TAAs) in AFP-negative HCC and normal control tissues.

Results: The frequency of autoantibodies to the three TAAs in AFP-negative HCC sera was 21.4%, 19.6% and 19.6%, which was significantly higher than in the chronic liver disease cases and normal human controls (P < 0.01) as well as AFP-positive HCC cases. The sensitivity of the three autoantibodies for diagnosis of AFP-negative HCC ranged from 19.6% to 21.4%, and the specificity was approximately 95%. When the three autoantibodies were combined, the sensitivity reached 30.4% and the specificity reached 91.6%.

Conclusion: Autoantibodies to NPM1, 14-3-3zeta and MDM2 may be useful biomarkers for immunodiagnosis of AFP-negative HCC.

Keywords: 14-3-3zeta; Autoantibody; Hepatocellular carcinoma; Immunodiagnosis; Mouse double minute 2 homolog; Nucleophosmin 1; α-fetoprotein.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declared that there is no conflict of interest related to this study.

Figures

Figure 1
Figure 1
Western blot analysis of representative sera of three anti-tumor-associated antigens autoantibodies assessed by enzyme-linked immunosorbent assay. Lane 1: The polyclonal anti-NPM1 autoantibody and anti-14-3-3zeta autoantibody were used as positive control; Lanes 2 and 3: Two representative AFP-negative HCC serum samples which were positive in ELISA also had strong reactivity to 14-3-3zeta recombinant protein in western blot analysis; Lanes 4 and 5: Randomly selected chronic liver disease sera and normal human control, respectively, with negative reactivity to 14-3-3zeta recombinant protein. AFP: Alpha fetoprotein; ELISA: Enzyme-linked immunosorbent assay; HCC: Hepatocellular carcinoma.
Figure 2
Figure 2
Analysis to determine the presence or absence of co-expression of antibodies to any combination of two of the three tumor-associated antigens in α fetoprotein-negative hepatocellular carcinoma, α fetoprotein-positive hepatocellular carcinoma, chronic liver disease and normal human control. The height of the bar represents the percentage of sera with co-expression of two antibodies, e.g., NPM1 antibody with 14-3-3zeta antibody, and NPM1 antibody with MDM2 antibody. AFP: Alpha fetoprotein; CLD: Chronic liver disease; HCC: Hepatocellular carcinoma; NHC: Normal human control; TAAs: Tumor-associated antigens.
Figure 3
Figure 3
Expression of NPM1, 14-3-3zeta and MDM2 in α-fetoprotein-negative hepatocellular carcinoma tissues and normal hepatic tissues by immunohistochemistry. The three polyclonal anti-TAAs antibodies were used as a primary antibody to detect their expression in liver cancer and normal hepatic tissues. A and B: HCC tissue with positive staining and normal hepatic tissue with negative staining in anti-NPM1 antibody; C and D: HCC tissue with strong positive staining and normal hepatic tissue with negative staining in anti-14-3-3zeta antibody; E and F: HCC tissue with strong positive staining and normal hepatic tissue with negative staining in anti-MDM2 antibody. AFP: Alpha fetoprotein; HCC: Hepatocellular carcinoma; TAAs: Tumor-associated antigens.
See this image and copyright information in PMC

References

    1. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410–433. - PubMed
    1. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1111–1118. - PubMed
    1. Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol. 2012;39:399–409. - PubMed
    1. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524–532. - PubMed
    1. Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013;87:121–131. - PubMed

MeSH terms